ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today ...

Fears that GLP-1 obesity drugs would reduce demand for ResMed’s various CPAP airflow machines have proven unfounded..

Bank of America Securities analyst Lyanne Harrison has reiterated their bullish stance on RMD stock, giving a Buy rating on October 10. Lyanne ...

The application of CPAP devices is considered as a backbone for people who have sleep apnea. These devices keep airways open ...

Left untreated, obstructive sleep apnea is linked to daytime sleepiness and an increased risk of anxiety, diabetes, ...

such as the AirTouch N30i next-generation CPAP mask unveiled earlier today. Capitalize on ResMed’s market opportunity and brand advantage in broader sleep health and breathing health adjacencies ...

Pottery Barn took on the challenge of housing a CPAP machine used to treat Obstructive ... with the condition can use to conceal those pesky masks, cords and hoses while still keeping them within ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Resmed (RMD – Research Report) and Abbott ...

Valued at $35.3 billion by market cap, San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications for ...

“New commercial excellence and demand generation initiatives will drive more patients into ResMed’s funnel, where they will be served by a robust road map of new products, such as the AirTouch N30i ...

ResMed chief executive Mick Farrell ... such as the AirTouch N30i next-generation CPAP mask.” The company said it would also seek to broaden its sleep health and breathing health offerings ...